AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
The AML-VAC-XS15-01 study was approved by the Ethics Committee of the Bavarian State medical association and the Paul-Ehrlich Institut (P01392). Clinical trial results will be published in peer-reviewed journals.
Authors
- Yacine Maringer (ORCID: https://orcid.org/0000-0002-2197-8740)
- Lisa Zieschang
- Helmut R. Salih (ORCID: https://orcid.org/0000-0002-6719-1847)
- Annika Nelde (ORCID: https://orcid.org/0000-0001-8504-8481)
- Jonas S. Heitmann (ORCID: https://orcid.org/0000-0002-7305-8620)
- Monika Denk
- Peter Martus (ORCID: https://orcid.org/0000-0002-5386-5732)
- Alexander Englisch
- Mustafa Özbek (ORCID: https://orcid.org/0000-0003-1125-3823)
- Christopher Hackenbruch
- Juliane S. Walz (ORCID: https://orcid.org/0000-0001-6404-7391)
- Christine Kammer
- Susanne Jung
Institutions
- German Cancer Research Center (DE)
- University Children's Hospital Tübingen (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-14
- DOI
- https://doi.org/10.3389/fonc.2024.1458449
- Citations
- 6
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.44
Funders
- Eberhard Karls Universität Tübingen
- Else Kröner-Fresenius-Stiftung